EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas

Zhaoxia Li, Wei Guo, Ou Bai

Frontiers in Oncology · 22.12.2023 · 13

DOI: 10.3389/fonc.2023.1301437 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 22.12.2023. Verfasst von Zhaoxia Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

At present, the treatment of lymphoma has entered the era of precision medicine, and CD30, as a transmembrane protein, has become an important marker to help the diagnosis and formulation of treatment plans for lymphomas. This protein is widely expressed in various types of lymphomas and can play a role through nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and other pathways, and ultimately lead to the up-regulation of CD30 expression to give tumor cells a survival advantage. Brentuximab vedotin (BV), as an antibody-drug conjugate (ADC) targeting CD30, is one of the first new drugs to significantly improve survival in patients with CD30+lymphomas. However, the biological function of CD30 has not been fully elucidated. Therefore, this review highlights the CD30-mediated tumor-promoting mechanisms and the molecular factors that regulate CD30 expression. We hope that a better understanding of CD30 biology will provide new insights into clinical treatment and improve the survival and quality of life of lymphoma patients.

Schlagwörter

Stichwörter der Autor:innen

BVCD30lymphomasmechanism of actiontargeted therapy

Autor:innen und Institutionen

  • Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China.

Zitieren

APA

Li, Z., Guo, W., & Bai, O. (2023). Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1301437

Vancouver

Li Z, Guo W, Bai O. Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1301437

BibTeX
@article{Li2023,
  author = {Li, Zhaoxia and Guo, Wei and Bai, Ou},
  title = {Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {13},
  doi = {10.3389/fonc.2023.1301437}
}
Kostenlos starten →